Scott E, et al. - This research was planned to describe the spectrum, incidence, kinetics, and management of endocrinopathies with immune checkpoint inhibitors. Compared to anti-PD-1 monotherapy, combination immunotherapy had a greater risk of development of endocrinopathy. Regular biochemical profiling of patients resulted in early detection of endocrinopathy to minimise morbidity, especially within the first 12 weeks.